Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02098954
What this trial is testing

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Who this might be right for
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Hunan Province Tumor Hospital 40
Early research (Phase 1)Study completedNCT02113813
What this trial is testing

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations
Astellas Pharma Global Development, Inc. 133
Testing effectiveness (Phase 2)Study completedNCT03861156
What this trial is testing

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Who this might be right for
Solid TumorNSCLCEGFR T790M
InventisBio Co., Ltd 290
Large-scale testing (Phase 3)Study completedNCT04206072
What this trial is testing

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerEGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd. 362
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06672068
What this trial is testing

TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Who this might be right for
NSCLC
TYK Medicines, Inc 60
Testing effectiveness (Phase 2)Looking for participantsNCT07518160
What this trial is testing

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Who this might be right for
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd. 35
Testing effectiveness (Phase 2)Study completedNCT05299125
What this trial is testing

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Metastatic Non-small Cell Lung Cancers
Latin American Cooperative Oncology Group 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Testing effectiveness (Phase 2)Study completedNCT02629523
What this trial is testing

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

Who this might be right for
Lung NeoplasmsEGFR Gene Mutation
Chonnam National University Hospital 21
Testing effectiveness (Phase 2)Looking for participantsNCT05503667
What this trial is testing

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Stage IIILung Adenocarcinoma Stage IVEGFR Gene Mutation
Shanghai Pulmonary Hospital, Shanghai, China 96
Not applicableStudy completedNCT04236102
What this trial is testing

KEBI-Cyto Study - Use of the Biocartis Idylla

Who this might be right for
Pancreatic AdenocarcinomaLung Cancer
Royal Cornwall Hospitals Trust 55
Testing effectiveness (Phase 2)WithdrawnNCT02355431
What this trial is testing

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Solid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma)
Incyte Corporation
Large-scale testing (Phase 3)Active Not RecruitingNCT04035486
What this trial is testing

Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 587
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Testing effectiveness (Phase 2)UnknownNCT04358562
What this trial is testing

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Who this might be right for
Non-small Cell Lung CancerEGFR Gene Mutation
Second Affiliated Hospital of Nanchang University 240
Not applicableLooking for participantsNCT05991193
What this trial is testing

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 100
Not applicableLooking for participantsNCT06659458
What this trial is testing

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

Who this might be right for
Lung Cancer - Non Small CellEGFR Exon 19 Deletion Mutation
Our Lady of the Lake Hospital 20
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)Looking for participantsNCT07058519
What this trial is testing

Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Who this might be right for
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 250
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Next Page